SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is seeing significant downward pressure driven by market apprehension surrounding Donald Trump's extended and often incoherent public address, where his discussion of tariffs and Greenland policy raises concerns about global trade stability. Community sentiment is deeply divided, with many expressing alarm over potential economic repercussions while a subset anticipates a swift "buy the dip" recovery from the current volatility.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amidst significant market volatility, fueled by discussions surrounding former President Trump's public statements on geopolitical issues, including Greenland and proposed tariffs, which are sparking international concern and market reactions. Community chatter is highly polarized, with supporters pointing to a new digital token initiative as a potential short squeeze catalyst, while critics link the former President's rhetoric to broader market instability and question the stock's underlying value.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is highly active amidst intense discussions fueled by geopolitical developments, specifically related to rhetoric from Davos concerning Greenland and potential tariffs impacting European allies. Community sentiment is bifurcated, with many anticipating continued declines from global instability and upcoming interest rate decisions, while a significant portion of traders are actively buying the dip, expecting a customary market rebound despite the contentious headlines.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending following a significant non-exclusive licensing agreement with Pfizer for its Matrix-M adjuvant technology, widely seen by the community as a validation of its core platform. This development has fueled expectations of further partnerships and a potential short squeeze, with many closely watching how management addresses continued activist investor pressure for enhanced shareholder value.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending dramatically after announcing promising Phase 1 clinical trial results for its oral drug, soquelitinib, treating moderate to severe atopic dermatitis with strong efficacy and a favorable safety profile. The market is actively discussing the drug's potential, especially for patients resistant to current therapies, driving speculation of significant upside and a short squeeze, though some caution against the early trial stage and potential dilution.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is a focal point of market discussion after recently upgrading its bid for Warner Bros. Discovery assets to an all-cash offer, a strategic move generating debate about its long-term growth prospects ahead of the upcoming earnings report. Community sentiment is sharply divided, with many seeing the stock as oversold and ripe for a rebound, while others express caution regarding the deal's implications and broader market headwinds.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple (AAPL) is currently experiencing highly polarized community sentiment, with many expressing frustration over its recent price decline, perceived lack of AI innovation, and broader market weakness. However, a strong counter-narrative highlights the stock as deeply oversold with historically low RSI levels, presenting a significant "buy the dip" opportunity ahead of its anticipated strong holiday quarter earnings. Geopolitical tensions and ongoing tariff discussions are further fueling volatility and shaping investor outlook on the tech giant.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is experiencing a surge in attention following a pivotal FDA meeting for its ANKTIVA bladder cancer treatment, where regulators reportedly indicated no requirement for new clinical trials and requested additional data for submission within 30 days. This news has ignited strong community discussion, with investors buzzing about a potential short squeeze and highlighting ANKTIVA's broad therapeutic promise across various cancer indications. The stock's robust performance amid a challenging market is drawing significant interest, as many anticipate further positive developments and substantial long-term growth for this biotech company.

ProShares Trust - ProShares Ultra VIX Short-Term Futures ETF 1.5x Shares

ProShares Ultra VIX Short-Term Futures ETF

UVXY is trending amid intensified geopolitical rhetoric and upcoming central bank decisions, driving speculation for a potential surge in market volatility. While some traders anticipate significant upward movement, the community largely discusses its inherent decay, making it a popular instrument for short-selling and a challenging long-term hold. This highlights the ongoing tug-of-war between event-driven fear and the structural nature of volatility products.

Top Wealth Group Holding Ltd. operates as a holding company, which provides caviar and caviar-based gourmet products. It focuses on supplying sturgeon caviar to customers under its own brand, Imperial Cristal Caviar. The company was founded by Kim Kwan Kings Wong on February 1, 2023 and is headquartered in Hong Kong.

Top Wealth Group Holding Ltd. - Ordinary Shares - Class A

Top Wealth Group Holding Ltd.

Top Wealth Group Holding is trending following news of its strategic acquisition of a luxury wine authentication and trading business, diversifying its market beyond caviar. This has ignited significant discussion among traders, with many anticipating further price movement and highlighting strong volume, while others express concerns about a recent public offering and potential dilution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

GoodRx (NASDAQ:GDRX) Upgraded at Wall Street Zen

Wall Street Zen raised shares of GoodRx from a "hold" rating to a "buy" rating in a research note on Saturday...

Surescripts and GoodRx Partner to Advance Patient Price Transparency

Surescripts, the nations leading health intelligence network, introduces its Patient Experience product, Script Corner, to transform the medication experience and empower patients by bringing...

Hims & Hers Expands Platform-Led Access to Provider-Directed Care

HIMS broadens access to provider-led care with new offerings in diagnostics, hormonal health and at-home testing.

GoodRx Launches RxSmartSaver at Giant Eagle Pharmacies

GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced the launch of RxSmartSaver powered by GoodRx at Giant Eagle pharmacies, giving patients a fast and easy...

<ul class="summary-bullets"><li>Hims shares logged their best session in a month and added after-hours gains.</li><li>Novo expanded oral Wegovy access, while Citi kept a ‘Sell’ rating on Hims.</li><li>Hims continues to broaden its platform through international expansion and new services.</li></ul>Hims &amp; Hers Health Inc. shares posted their strongest session in a month on Monday and added another 0.7% in after-hours trading, with both trading days so far this year ending higher.The move came despite a cautious note from Citi, which said Novo Nordisk’s latest Wegovy announcement could pressure Hims’ GLP-1 business in 2026. Citi kept a 'Sell' rating on the stock with a $30 price target.<h2 class="st-heading-2">Novo’s Oral Wegovy Move Leaves HIMS On The Sidelines</h2>Novo Nordisk said on Monday that its oral Wegovy pill is now broadly available in the U.S., with pricing starting at $149 a month for specific doses and higher prices for larger doses later in 2026. Novo also said commercially insured patients could access the pill for as low as $25 per month.Citi said Hims was again left off Novo’s list of partners, which includes CVS Health, Costco, LifeMD and GoodRx. The firm said this likely reflects disagreements between Novo and Hims around Hims’ compounded semaglutide strategy, and added that the broader rollout of Wegovy pills could put pressure on Hims’ GLP-1 business this year.<h2 class="st-heading-2">Broader Growth Drivers Remain in Focus</h2>Hims &amp; Hers Health has spent recent months expanding its platform beyond weight loss through geographic expansion, new product launches and acquisitions. In December, the company announced the expansion of its Weight Loss Program to the UK, including the official launch of the Hers platform for eligible women, offering access to weight-management care following assessments by GMC-registered doctors. The UK offering includes branded GLP-1 options and oral non-prescription treatments.Hims has also entered Canada following the completion of its acquisition of Livewell, a Canadian digital health platform. Additionally, the company said it will acquire YourBio Health, which develops capillary whole blood sampling technology, including the TAP device that uses bladeless microneedles.&nbsp;Separately, Hims launched its Labs in-depth testing experience, which provides customers with blood-based biomarker testing and doctor-developed action plans across areas such as heart health, metabolism, hormones and inflammation. The company said it plans to expand the Labs offering over time to include additional biomarker tests, at-home testing devices and advanced diagnostics.In December, Barclays initiated coverage of Hims with an ‘Overweight’ rating and a $48 price target, noting that expectations for the business had become more reasonable and pointing to the addition of other growth drivers for FY26.<h2 class="st-heading-2">Investors Look Beyond Near-Term GLP-1 Pressure</h2>Competition in the GLP-1 weight-loss space continues to broaden. Novo Nordisk and Eli Lilly dominate the market with Wegovy and Zepbound, respectively, and Lilly’s injectable Zepbound has been shown in a head-to-head study to deliver greater average weight loss than Wegovy. Novo has since launched the first FDA-approved oral GLP-1 for weight loss, while Lilly is advancing its own oral candidate, orforglipron, which is under regulatory review. Both companies have also cut cash-pay prices for lower doses as access expands beyond insurance-covered channels.Beyond Novo and Lilly, other drugmakers are developing next-generation obesity treatments, including Lilly’s retatrutide and Novo’s CagriSema, while additional companies such as Pfizer and Structure Therapeutics are working on oral weight-loss drugs.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment was ‘bullish’ amid ‘high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/hims_ss_png_55bef6044e.webp" alt="hims ss.png" width="972" height="144"><figcaption>HIMS sentiment and message volume as of January 5| Source: Stocktwits</figcaption></figure>One user said, “Injections vs pills for weight loss will be a big deal. Who wouldnt rather take a pill. HIMS needs to get Novo deal or somehow get access to sell the pill, otherwise their weight loss related revenue will tank”<stembedurl>https://stocktwits.com/Matril/message/640906333</stembedurl>Another user said that with GLP-1 pills now available through large retailers such as Costco, the downside risks are already reflected in the stock price, and added that future catalysts could include share buybacks and increased trading activity.<stembedurl>https://stocktwits.com/ros_/message/640880655</stembedurl><a href="https://stocktwits.com/symbol/HIMS">Hims’ stock</a> has risen 30% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a smartphone displays the logo of Hims & Hers Health in front of a screen showing the company's stock market chart. (Photo illustration by Cheng Xin/Getty Images)

Hims & Hers Enters 2026 On Solid Ground — Stock Rises Even After Novo Nordisk Leaves It Off Wegovy Partner List

The development comes as attention remains on Hims’ longer-term business expansion initiatives.

Equity

GoodRx Now Offers Novo Nordisks Cash Price for the Launch of the Wegovy Pill

GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced that the newly FDA-approved Wegovy pill (oral semaglutide) is now available at a cash price of $149 per...

GoodRx Holdings, Inc. (NASDAQ:GDRX) Given Consensus Recommendation of "Hold" by Brokerages

Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) have received an average rating of "Hold" from the fourteen research firms that are currently covering the stock, Marketbeat reports...

Pacer Advisors Inc. Makes New Investment in GoodRx Holdings, Inc. $GDRX

Pacer Advisors Inc. purchased a new position in GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and...

Tempus AI Approaching Profitability Despite GAAP Losses

TEM shows early profitability inflection with first positive Adjusted EBITDA in Q3 2025, raised revenue guidance and disciplined spending despite GAAP losses.

GoodRx to Participate in the 44th Annual J.P. Morgan Healthcare Conference

GoodRx Holdings, Inc. (Nasdaq: GDRX) (GoodRx or the Company), the leading platform for medication savings in the U.S., today announced that executives from the Company will participate in a fireside...

GoodRx Holdings, Inc. engages in the business of a consumer-focused digital healthcare platform. It offers consumers free access to transparent and lower prices for brand and generic medications, affordable and convenient medical provider consultations via telehealth, and comprehensive healthcare research and information. The company was founded by Trevor Bezdek and Douglas Joseph Hirsch in September 2011 and is headquartered in Santa Monica, CA.

GoodRx Holdings Inc - Ordinary Shares - Class A

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	$0.09	--	--	N/A
Q3 '25	$0.09	$0.08	-11.40%	MISSED
Q2 '25	$0.10	$0.09	-8.74%	MISSED
Q1 '25	$0.10	$0.09	-5.40%	MISSED
Q4 '24	$0.08	$0.09	9.97%	BEAT

GDRX
GoodRx Holdings Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest GDRX News

GDRXGoodRx Holdings Inc